Recombinant IL5 (Mepolizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- IL5 (Mepolizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
- Host
-
Mammalian Cells
- Expression System
- Mammalian cells
- Clonality
- Monoclonal
- Application
- ELISA
- Purpose
- Mepolizumab Biosimilar - Anti-IL5 mAb
- Characteristics
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- IL5 (Mepolizumab Biosimilar)
- Target Type
- Biosimilar
- Background
-
SB-240563
Mepolizumab is a fully humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. (EGPA) and eosinophilia syndrome (HES). The pathogenesis of eosinophils is complex, but IL-5 is considered a key eosinophilic factor, involved in the differentiation, recruitment, activation and prolonged survival of eosinophils in peripheral tissues. Activated eosinophils further stimulate the inflammatory response, and also induce tissue damage and promote fibrosis, all of which contribute to the multifactorial symptoms of eosinophilic disease. Mepolizumab is used to treat severe asthma. - CAS-No
- 196078-29-2
-
You are here:
